| PNK | polynucleotide kinase; pyridoxine kinase |
|---|---|
| RK | rabbit kidney; radial keratotomy; reductase kinase; rhodopsin kinase; right kidney |
| ADRBK | beta-1-adrenergic receptor kinase |
| BARK | beta-adrenergic receptor kinase |
| CR | calculation rate; calculus removed; calorie-restricted; cardiac rehabilitation; cardiac resuscitatio... |
| tyrosine N-monooxygenase | <enzyme> Catalyses the n-hydroxylation of l-tyrosine to n-hydroxytyrosine Registry number: EC 1.14.13.41 Synonym: tyrosine n-hydroxylase, haemthiolate enzyme, cytochrome p450(tyr), cyp79 protein (26 Jun 1999) |
|---|---|
| tyrosine phenol-lyase | <enzyme> An enzyme that catalyses the cleavage of tyrosine to phenol, pyruvate, and ammonia. It is a pyridoxal phosphate protein. The enzyme also forms pyruvate from d-tyrosine, l-cysteine, s-methyl-l-cysteine, l-serine, and d-serine, although at a slower rate. Chemical name: L-Tyrosine phenol-lyase (deaminating) Registry number: EC 4.1.99.2 (12 Dec 1998) |
| tyrosine phosphorylation | <enzyme> Kinases that phosphorylate protein tyrosine residues. These kinases play major roles in mitogenic signalling and can be divided into two subfamilies: receptor tyrosine kinases, that have an extracellular ligand binding domain, a single transmembrane domain and an intracellular tyrosine kinase domain and nonreceptor tyrosine kinases, which are soluble, cytoplasmic kinases. (18 Nov 1997) |
| tyrosine-repressible transaminase | <enzyme> From E coli; catalyses the amination of 2-ketoisocaproate to leucine; encoded by tyrb; a functional leuabcd operon is required for leucine synthesis by this enzyme Registry number: EC 2.6.1.- Synonym: transaminase d, tyrosine-2-ketoisocaproate aminotransferase (26 Jun 1999) |
| tyrosine transaminase | <enzyme> An enzyme that catalyses the conversion of l-tyrosine and 2-oxoglutarate to 4-hydroxyphenylpyruvate and l-glutamate. It is a pyridoxal-phosphate protein. L-phenylalanine can act instead of l-tyrosine. The mitochondrial enzyme may be identical with aspartate transaminase (ec 2.6.1.1.). Chemical name: L-Tyrosine:2-oxoglutarate aminotransferase Registry number: EC 2.6.1.5 (12 Dec 1998) |
| tyrosine-trna ligase | <enzyme> An enzyme that activates tyrosine with its specific transfer RNA. Chemical name: L-Tyrosine:tRNA-(Tyr) ligase (AMP-forming) Registry number: EC 6.1.1.1 (12 Dec 1998) |
| L-tyrosine ammonia-lyase | <enzyme> Catalyses the conversion of tyrosine to trans-p-coumaric acid and ammonia Registry number: EC 4.3.1.- Synonym: tyrosine ammonia-lyase (26 Jun 1999) |
| acetylcholine receptor antibodies | <neurology, investigation> A test used to measure the amount of antibodies to acetylcholine receptors on nerve endings. This is a diagnostic test for myasthenia gravis. A normal value is no antibodies in the bloodstream. Acetylcholine receptor (AChR) binding autoantibodies (i.e. Antibodies reactive with several epitopes other than the binding site for acetylcholine or alpha-bungarotoxin) are present in approximately 88% of patients with generalised myasthenia gravis, 70% of ocular myasthenia and in approximately 80% of myasthenia gravis in remission. Although serum concentrations of AChR binding autoantibodies do not in general correlate well with severity of weakness, there is typical decrease in concentration as weakness improves with immunosuppressive therapy. AChR blocking autoantibodies (i.e., antibodies reactive with the AChR binding site) are present in about 50% of patients with myasthenia gravis, 30% with ocular myasthenia gravis and 20% of myasthenia gravis in remission, AChR blocking autoantibodies are the only AChR autoantibodies present in about 1% of myasthenia gravis. AChR modulating autoantibodies (i.e., autoantibodies which cross-link AChRs and cause their removal from muscle membrane surfaces) are present in more than 90% of myasthenia gravis and occasionally are the only AchR autoantibodies detectable in mild, recent onset or ocular-restricted myasthenia gravis. Results for AChR modulating autoantibodies can be transiently false-positive due to curare-like drugs used during general anesthesia. AChR autoantibodies of one or more types are found in at least 80% of ocular myasthenia gravis. Although generally absent in neurological conditions other than myasthenia gravis(and consequently unlikely to cause confusion in neurodiagnosis), false-positive results for AChR autoantibodies occasionally occur in primary biliary cirrhosis, tardive dyskinesia, autoimmune thyroiditis, the elderly, amyotrophic lateral sclerosis patients treated with cobra venom and patients with thymoma in the absence of myasthenia gravis. Approximately 1% of patients with rheumatoid arthritis treated with D-penicillamine develop AChR autoantibodies and myasthenia gravis, both of which disappear when the drug is discontinued. Babies born to ~10% of myasthenia gravis mothers have a transient neonatal form of myasthenia gravis that responds well to anticholinesterase therapy and usually remits within 1 month as maternal IgG disappears. (29 Dec 1997) |
| amino acid receptor | <biochemistry> Ligand gated ion channels with specific receptors for amino acid transmitters. An extended protein superfamily that also includes subunits of the nicotinic acetylcholine receptor. (18 Nov 1997) |
| AMPA receptor | <cell biology> Glutamate operated ion channel. See: excitatory amino acid receptor channels. (05 Feb 1998) |
| ANP receptor | <molecular biology> Family of 3 receptors for atrial natriuretic peptide. ANP A and ANP B have intracellular guanylate cyclase and protein kinase like domains. ANP C, shares the extracellular ligand binding and transmembrane domains, but lacks the functional intracellular domains and is not thought to be involved in signal transduction. (18 Nov 1997) |
| asialoglycoprotein receptor | A surface receptor found in hepatocytes that binds galactose-terminal glycoproteins; thus, this receptor removes those proteins from circulation and they are in turn acted upon by hepatocyte lysosomes. (05 Mar 2000) |
| auditory receptor cells | Columnar cell's in the epithelium of the organ of Corti, having hairs (stereocilia) on their apical ends. See: Corti's cells. (05 Mar 2000) |
| beta-adrenergic receptor blocking agent | A class of drugs that compete with beta-adrenergic agonists for available receptor sites; some compete for both b1 and b2 receptors (e.g., propranolol) while others are primarily either b1 (e.g., metoprolol) or b2 blockers; used in the treatment of a variety of cardiovascular diseases where beta-adrenergic blockade is desirable. Synonym: beta-adrenergic receptor blocking agent, beta-adrenoreceptor antagonist, beta-blocker. (05 Mar 2000) |
| cAMP receptor protein | catabolite (gene) activator protein |